Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.44 |
| ▸ | CLK3 | P49761 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530749 | 1.00 | CYP1A2 (0.56) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL29530397 | 0.87 | CYP1A2 (0.44) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL29530507 | 0.84 | CLK1 (0.44) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL1024738 | 0.84 | CLK1 (0.44) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL1606431 | 0.82 | CYP1A2 (0.57) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL11640386 | 0.81 | ALDH1A1 (0.40) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3251286 | 0.80 | CYP1A2 (0.56) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3785439 | 0.80 | ALDH1A1 (0.42) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL30751778 | 0.79 | XDH (0.45) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL249967 | 0.79 | CA12 (0.49) | CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551029-B | Synthesis method of 4-bromo-3-cyanopyridine | HENAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-117551029-A | Synthesis method of 4-bromo-3-cyanopyridine | 河南大学 | 2024-02-13 | — | — | CN | claimed |
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | claimed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | claimed |
| CN-110759860-B | Preparation method of 3-methyl formate-4-methoxy-5-cyanopyridine | 江苏瑞科医药科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-111153825-A | Method for preparing amide compound by using supported metal oxide catalytic material | 浙江大学 | 2020-05-15 | — | — | CN | claimed |
| EP-3207030-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-08-23 | — | — | EP | claimed |
| WO-2016060941-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | WO | claimed |
| WO-2004084801-A2 | TREATMENTS FOR LEISHMANIASIS | SMITHSONIAN TROPICAL RESEARCH INSTITUTE (US) | 2004-10-07 | — | — | WO | claimed |
| CN-117551029-B | Synthesis method of 4-bromo-3-cyanopyridine | HENAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117551029-B | Synthesis method of 4-bromo-3-cyanopyridine | HENAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122068113-A | Battery monomer, preparation method thereof, battery device and energy storage device | 浙江晶科储能有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-118001338-A | A Chinese medicinal composition for treating breast nodule and hyperplasia of mammary glands, and its preparation method | 哈尔滨医科大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1005446-B1 | N-AROYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | WDR5, WDR1, WDR77 | CYP1A2 2860/4885CYP2E1 2551/4885CYP2A6 3159/4885 |
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR1A | CYP1A2 316/4885CYP2E1 230/4885CYP2A6 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.